{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-020209","form_type":"8-K","ticker":"NMRK","cik":"0001690680","company_name":"NEWMARK GROUP, INC.","filed_at":"2021-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.696143+00:00","generated_at":"2026-06-28T20:00:54.190873+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Chairman Howard Lutnick discloses Non-Hodgkin's Lymphoma diagnosis, expects full recovery in 4 months","bullets":["Howard Lutnick diagnosed with highly treatable Non-Hodgkin's Lymphoma; expects to be cancer-free in 4 months.","Treatment includes six chemotherapy sessions from Oct 18, 2021 through end of Jan 2022.","Lutnick plans to continue serving as Chairman during treatment period."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-020209","json":"https://secwatch.observer/filing/0001628280-21-020209.json","markdown":"https://secwatch.observer/filing/0001628280-21-020209.md","text":"https://secwatch.observer/filing/0001628280-21-020209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690680/000162828021020209/0001628280-21-020209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690680/000162828021020209/nmrk-20211018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:00:54.190873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}